Regeneron Pharmaceuticals, Inc.: PharmaVitae Report

  • ABOUT THIS REPORT
    • PharmaVitae Explorer database
    • Chapter structure
      • Sales and product analysis
      • Financial analysis
    • Data sourcing
      • Analyst consensus
  • EXECUTIVE SUMMARY
    • Company introduction
      • Recent developments
      • Corporate relationships
      • Bayer
      • Astellas
      • Novartis
      • Roche/Genentech
    • Strategic overview
    • SWOT analysis
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • SALES AND PRODUCT ANALYSIS
    • Sales overview
    • Product analysis
      • Product sales
    • Eylea (intraocular aflibercept; VEGF Trap-Eye)
      • Disease background
      • CATT trial
      • Retinal vein occlusion
      • Diabetic macular edema
      • Wet AMD clinical trials
      • Opinions of Eylea
      • Use in retinal vein occlusion and diabetic macular edema
      • BRVO trial
      • DME trial
      • Current use of anti-VEGF agents in RVO and DME
      • Key forecasting assumptions
      • CRVO
      • BRVO
      • DME
    • Zaltrap (intravenous aflibercept; VEGF-Trap)
      • Colorectal cancer clinical trials
      • Several factors may impact Zaltrap’s uptake in the second-line setting
      • Sanofi’s presence in the colorectal cancer market will aid commercialization of Zaltrap
      • Key forecasting assumptions
    • Arcalyst (rilonacept)
      • Arcalyst CAPS sales to remain flat through forecast period
      • Gout background
      • Gout clinical trials
      • Approval of Arcalyst for the prevention of gout flares appears unlikely following negative FDA panel vote
    • Sarilumab (REGN88; IL-6R antibody)
    • REGN727 (SAR236553; PCSK9 antibody)
      • Regeneron and Sanofi have not disclosed plans for REGN727 Phase III development
    • Earlier-stage products
      • REGN475 (SAR164877; NGF antibody)
      • REGN668 (SAR231893; IL-4R antibody)
      • REGN421 (SAR153192; Dll4 antibody)
      • REGN910 (SAR307746; Ang2 antibody)
      • REGN846
      • REGN728
      • REGN1033
      • REGN1154
  • FINANCIAL ANALYSIS
    • Financial performance overview
      • Operating costs and profit analysis, 2005–11
      • Operating costs and profit analysis, 2011–17
  • APPENDIX
    • References
      • Datamonitor reports
    • Exchange rates
  • TABLES
    • Table: Regeneron R&D pipeline
    • Table: Regeneron catalyst timeline
    • Table: Regeneron product portfolio overview ($m), 2011–17
    • Table: Regeneron/Bayer-sponsored Eylea clinical trials, ongoing
    • Table: Overview of pivotal Phase III data for Eylea in wet AMD
    • Table: Overview of pivotal Phase III data for Eylea and Lucentis in macular edema secondary to CRVO
    • Table: Eylea US wet AMD forecast model, 2012–17
    • Table: Eylea US RVO forecast model, 2012–17
    • Table: Eylea US DME forecast model, 2012–17
    • Table: Worldwide Eylea sales, 2012–17
    • Table: Zaltrap colorectal cancer clinical trials
    • Table: Summary of results from the Phase III VELOUR trial
    • Table: Zaltrap sales forecast, seven major markets ($m), 2012–17
    • Table: Arcalyst gout Phase III trials
    • Table: Summary of results from the Phase III PRE-SURGE trials
    • Table: Sarilumab trials
    • Table: Summary of results from the Phase IIb portion of the MOBILITY trial
    • Table: REGN727 trials
    • Table: Regeneron operating revenue/cost analysis ($m), 2005–11
    • Table: Regeneron operating revenue/cost analysis ($m), 2011–17
    • Table: Exchange rates, 2011
  • FIGURES
    • Figure: PharmaVitae Explorer
    • Figure: Regeneron prescription pharmaceutical performance, sales ($m) and growth rate (%), 2011–17
    • Figure: Regeneron sales ($m), 2011–17
    • Figure: In October 2011 (immediately prior to the approval of Eylea), what percentage of your treated wet AMD patients were receiving the following treatments?
    • Figure: Following the 2-year results of the CATT trial, how do you view Avastin versus Lucentis in terms of efficacy/safety?
    • Figure: Based on your knowledge of the three anti-VEGF agents, please rate them on a scale from 1 to 5 on the following attributes, where 1=poor and 5=excellent.
    • Figure: Of the patients to whom you have administered Eylea, what percentage falls into each of the following categories? (Weighted average)
    • Figure: So far this year, what percentage of your newly diagnosed patients received the following agents as their first-line therapy? Three years from now, what percentage of your newly diagnosed patients do you expect will receive the following agents as their first-line therapy?
    • Figure: Of your patients failing their first-line therapy, what percentage do you expect will receive Avastin, Lucentis, or Eylea as a second-line therapy?
    • Figure: Of your CRVO/BRVO/DME patients, what percentages are currently treated with the following?
    • Figure: Regeneron operating/cost performance ($m), 2005–17

Report

Published by
Datamonitor
Published on
31 May 2012
Product code
HC00212-014
Pages
Please wait...

$5700

Multi-user License $14250